TriSalus Life Sciences Inc. (TLSI)
NASDAQ (NMS) NASDAQ (NMS) Primary 
TriSalus Life Sciences Q1 Earnings Call Highlights
TriSalus Life Sciences NASDAQ: TLSI reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.33 per share a year ago.
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Upgraded to Buy: Here's What You Should Know
TriSalus Life Sciences, Inc. (TLSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript
TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript
TriSalus Life Sciences, Inc. ( TLSI ) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization November 12, 2025 10:00 AM EST Company Participants Mary Szela - CEO, President & Director Richard Marshall Andrea Marasso Conference Call Participants Nicole Lamparello Francis Kang Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning, and welcome to the TriSalus Life Sciences KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the TriSalus website following the conclusion of the event.
TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 AM ET Company Participants David B. Patience - Chief Financial Officer Jeremy Feffer - Corporate Participant Mary T.
TriSalus Life Sciences, Inc. (TLSI) Reports Q2 Loss, Tops Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.21 per share a year ago.
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.54 per share a year ago.
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?
TriSalus Life Sciences, Inc. (TLSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks
TriSalus Life Sciences aims to achieve positive cash flow by 2025, driven by expanding sales of their TriNav system and reducing operating expenses. The PERIO-03 trial for nelitolimod, a potential treatment for liver-involved cancers, is a key catalyst, with top-line data expected later this year. Financially, TLSI reported a net loss of $30 million for FY 2024, but expects to be EBITDA positive with 50% sales growth in 2025.
TriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive Officer James Young - Chief Financial Officer Richard Marshall - Medical Director Conference Call Participants Carl Burns - Northland Capital Markets Justin Walsh - JonesTrading Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company William Plovanic - Canaccord Genuity Operator Good morning, and welcome to TriSalus Life Sciences Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all participants are in a listen-only mode.
